Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289739 | 0.91 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4276106 | 0.88 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4283358 | 0.87 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13573956 | 0.86 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4288011 | 0.85 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4284772 | 0.85 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4289112 | 0.85 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4282150 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4280253 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4277148 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160038490-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2016-02-11 | — | — | US | claimed |
| WO-2014093960-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2014-06-19 | — | — | WO | claimed |
| US-20160038490-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20150164907-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2015-06-18 | — | — | US | disclosed |
| WO-2009153566-A1 | CYP26 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153566-A1 | CYP26 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038490-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | DUSP6, CYP26B1, CYP26A1 | CYP26A1 3/4885CYP1A2 165/4885CYP3A4 458/4885 |
| US-20150164907-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | CDK6, DUSP6, CYP26B1 | CYP26A1 11/4885CYP1A2 710/4885CYP3A4 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.